HPLC of Formula: 350-30-1On September 1, 2020 ,《Structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK inhibitors blocking WNK kinase signaling》 was published in Bioorganic & Medicinal Chemistry Letters. The article was written by Fujii, Shinya; Kikuchi, Eriko; Watanabe, Yuko; Suzuyama, Honoka; Ishigami-Yuasa, Mari; Mori, Takayasu; Isobe, Kiyoshi; Uchida, Shinichi; Kagechika, Hiroyuki. The article contains the following contents:
We report here structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK (STE20/SPS1-related proline/alanine-rich kinase) inhibitors. Abnormal activation of the signal cascade of with-no-lysine kinase (WNK) with OSR1 (oxidative stress-responsive kinase 1)/SPAK and NCC (NaCl cotransporter) results in characteristic salt-sensitive hypertension, and therefore inhibitors of the WNK-OSR1/SPAK-NCC cascade are candidates for antihypertensive drugs. Based on the structure of lead compound 2, we examined the SAR of N-(4-phenoxyphenyl)benzamide derivatives, and developed compound 20l as a potent SPAK inhibitor. Compounds 201 is a promising candidate for a new class of antihypertensive drugs. In the experiment, the researchers used 3-Chloro-4-fluoronitrobenzene(cas: 350-30-1HPLC of Formula: 350-30-1)
3-Chloro-4-fluoronitrobenzene(cas: 350-30-1) belongs to organochlorine compounds. The wide structural variety and divergent chemical properties of organochlorides lead to a broad range of names, applications, and properties. Organochlorine compounds have wide use in many applications, though some are of profound environmental concern, with TCDD being one of the most notorious.HPLC of Formula: 350-30-1
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics